VIP Entertainment Technologies Inc.
VETIF News Today: Stay Updated with the Latest VIP Entertainment Technologies Inc. News in Real Time
Find VETIF news now at Meyka AI. Stay informed with the latest VIP Entertainment Technologies Inc. stocks updates, including price news, market analysis, and expert insights.
DNUT: Krispy Kreme CFO Sells 2,493 Shares on May 15, 2026
Krispy Kreme CFO Raphael Duvivier sold 2,493 shares at $3.25 per share on May 15, 2026. SEC Form 4 filing details.
QBCRF Maintained at Sector Perform by RBC, Scotiabank May 2026
RBC Capital and Scotiabank raised QBCRF price targets on May 15, 2026, maintaining Sector Perform ratings for Quebecor Inc.
HTSUY Stock Surges 140,215% as Hisamitsu Pharmaceutical Rebounds
HTSUY stock jumps 140,215% to $4.55 on Pink Sheets. Hisamitsu Pharmaceutical rebounds sharply on technical recovery.
BWIN: General Counsel Cohen Sells 15,000 Shares May 18, 2026
BWIN insider Cohen Seth Bala sold 15,000 shares at $20.01 on May 14, 2026. General Counsel disposition signals executive liquidity move.
PSKY Maintained at Overweight by UBS May 2026
UBS maintains Paramount Skydance (PSKY) at Overweight rating on May 15, 2026, amid streaming competition and market headwinds.
Trial Holdings Inc Stock Tumbles 31.8% on Valuation Concerns
141A.T stock crashes 31.8% to Β₯2,911 as Meyka AI rates discount retailer with C grade. Market cap hits Β₯437.8B on JPX.
Real Brands Stock Surges 504,550% on Massive Volume Spike
RLBD stock explodes with 1M+ volume surge. Real Brands trades at $0.00001 on PNK exchange amid extreme volatility.
AMD Outpaces SPY With 98% YTD Surge While S&P 500 ETF Gains 8.4%
The semiconductor giant AMD has delivered one of the strongest performances in the stock market this year, surging nearly 98% year-to-date (YTD). In contrast, the broader market tracked by the S&P 500 ETF (SPY) has gained only around 8.4% over the same period. This sharp difference highlights the growing impact of technology and AI stocksβ¦
OncoTherapy Science Stock Tumbles 4.8% on Biotech Headwinds
OncoTherapy Science (4564.T) drops 4.8% to Β₯20.0 amid clinical trial challenges and sector weakness in Japanβs biotech market.